Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Brigham and Women's Hospital · Harvard University · +2 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,302
total citations
- FWCI
- 56.62
- Percentile
- 100%
- References
- 34
Citations per year
Authors
119- PMPaul M. RidkerCorresponding
Brigham and Women's Hospital, Harvard University
- JMJean MacFadyen
Brigham and Women's Hospital, Harvard University
- TTTom Thurén
Novartis (Switzerland), Novartis (United States)
- BMBrendan M Everett
Brigham and Women's Hospital, Harvard University
- PLPeter Libby
Brigham and Women's Hospital, Harvard University
Topics & keywords
Topics
Keywords
- Canakinumab
- Medicine
- Placebo
- Internal medicine
- Lung cancer
- Cancer
- Clinical endpoint
- Randomized controlled trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.